Loading organizations...
Based in Munich, Germany, Complement Therapeutics is a clinical-stage biotechnology company developing novel gene therapies targeting the complement system to treat complement-mediated diseases such as geographic atrophy. The firm focuses primarily on the field of ophthalmology, advancing its lead candidate, CTx001, which recently received Investigational New Drug clearance from the FDA for the treatment of dry age-related macular degeneration. To support its preclinical and clinical development programs, the enterprise has raised €77 million in total venture capital funding across multiple rounds. This financial backing includes a €5 million seed round and a €72 million Series A financing supported by prominent life sciences investors such as Gimv, Forbion, BioGeneration Ventures, and Cambridge Innovation Capital. Complement Therapeutics was founded in 2022 as a research spinout from the University of Manchester by Simon J. Clark, Paul Bishop, and Richard Unwin.
Complement Therapeutics has raised $85.0M across 2 funding rounds.
Complement Therapeutics has raised $85.0M in total across 2 funding rounds.
Complement Therapeutics has raised $85.0M across 2 funding rounds. Most recently, it raised $79.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2023 | $79M Series A | Forbion, Michaël Vlemmix | Andera Partners, MAX Klement, Cambridge Innovation Capital, EQT Life Sciences, Kurma Partners, Sanofi Ventures, Ysios Capital, BioGeneration Ventures, Roger Franklin, ROB Woodman, Seroba Life Sciences | Announced |
| Feb 1, 2022 | $6M Seed | BGV (biogeneration Ventures), Forbion | Andera Partners, EQT Life Sciences, Kurma Partners, Sanofi Ventures, Ysios Capital | Announced |
Complement Therapeutics has raised $85.0M in total across 2 funding rounds.
Complement Therapeutics's investors include Forbion, Michaël Vlemmix, Andera Partners, Max Klement, Cambridge Innovation Capital, EQT Life Sciences, Kurma Partners, Sanofi Ventures, Ysios Capital, BioGeneration Ventures, Roger Franklin, Rob Woodman.
Complement Therapeutics (CTx) is a clinical-stage biotechnology company developing novel therapeutics for complement-mediated diseases, particularly targeting geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness affecting over 5 million people globally[1][2][5]. Its lead product, CTx001, is an investigational AAV-based gene therapy designed as a potential one-time treatment to modulate multiple complement pathways, addressing unmet needs in complement dysregulation through gene therapies, protein-based approaches, and a proprietary mass spectrometry platform for precision medicine[1][2][5]. Headquartered in Munich, Germany, with subsidiaries in the UK and USA, CTx serves patients with ocular and systemic complement-related diseases, solving the problem of limited durable treatments for conditions like GA by advancing from preclinical to Phase I/II trials (Opti-GAIN) following FDA IND clearance in 2025[2]. The company shows strong growth momentum, progressing from a 2020 university spinout to clinical-stage in four years, backed by investors like Forbion[1][2].
Complement Therapeutics spun out from the University of Manchester in 2020, leveraging ground-breaking research by its founders on the role of the complement system in ocular and systemic diseases, including AMD[1][2][5]. This translational research provided novel insights into complement dysregulation, forming the basis for its therapeutic platforms[5]. Key leadership includes CEO Rafiq Hasan, who has guided the company from spinout to clinical-stage, and board members like Anne Horgan; the firm's international reputation in complement biology drove early traction, including the natural history study i-GAIN enrolling over 230 participants[1][2][3]. Pivotal moments include FDA IND clearance for CTx001 in October 2025, enabling the first-in-human Opti-GAIN Phase I/II trial, and investor support from Forbion, highlighting rapid evolution in biotech[1][2].
Complement Therapeutics rides the wave of complement biology innovation in biotech, fueled by growing recognition of complement dysregulation in diseases like AMD and rising adoption of complement inhibitors, with the GA market projected to surge through 2034[3]. Timing is ideal amid FDA approvals for GA therapies and gene therapy advances, amplified by market forces such as aging populations driving AMD prevalence and demand for one-time treatments over chronic injections[1][2][3]. CTx influences the ecosystem by pioneering precision diagnostics and multi-pathway modulation, potentially setting standards for complement-mediated therapies beyond ophthalmology, while its spinout model exemplifies Europe's biotech momentum with cross-border operations[1][2][4][5].
Complement Therapeutics is poised to disrupt GA treatment with Opti-GAIN trial data expected to validate CTx001's safety, tolerability, and efficacy, potentially accelerating partnerships or further funding[2]. Trends like expanding gene therapy adoption, complement-targeted drugs, and precision medicine will shape its path, with additional programs in systemic diseases broadening its pipeline[1][2]. Its influence may evolve from niche innovator to ecosystem leader if CTx001 succeeds, transforming AMD care and inspiring complement-focused spinouts—echoing its origin as a research breakthrough now entering the clinic[5].
